AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17201996
Drug: R,S‐citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R,S‐citalopram (20 mg)
Trial: 17201996
Drug: S‐citalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐citalopram (10 mg)
Trial: 15170981
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) and l-leucovorin (l-LV) given monthly (arm A)
Trial: 15170981
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) and l-leucovorin (l-LV) given every 2 months (arm B)
Trial: 11408900
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate (25 mg) injected once per week for 5 weeks
Trial: 11408900
Drug: Dexamethasone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (2 mg) injected once per week for 5 weeks
Trial: 11408900
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (SH and steroid)
Trial: 2892862
Drug: Prazosin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin administration
Trial: 26733057
Drug: Ovaleap® (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovaleap® (150 IU/day for 5 days, then dose-adjusted up to 450 IU/day)
Trial: 26733057
Drug: Gonal-f® (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonal-f® (150 IU/day for 5 days, then dose-adjusted up to 450 IU/day)
Trial: 25069431
Drug: Fluoxetine or
RxNorm normalized name: fluoxetine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine or tianepine with cognitive-behavioral therapy, supportive therapy, or psychodynamic therapy
Trial: 21627399
Drug: Turmeric supplementation
RxNorm normalized name: Turmeric
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric supplementation (500 mg per capsule, 3 capsules daily for 2 months)
Trial: 21627399
Drug: Placebo (starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch capsules identical in colour and size)
Trial: 10765039
Drug: Intravenous cefotiam
RxNorm normalized name: cefotiam
DrugBank: Cefotiam (DB00229)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cefotiam dihydrochloride (CTM) 2 g on induction of anesthesia
Trial: 10765039
Drug: Oral cefpodoxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cefpodoxime proxetil (CPDX-PR) 100 mg twice daily from day 0 to day 2
Trial: 1321542
Drug: 1.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg.kg‐1 suxamethonium preceded by 10 mg gallamine
Trial: 6376208
Drug: Chlorthalidone 50
RxNorm normalized name: chlorthalidone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 50 mg/triamterene 50 mg once-daily oral doses
Trial: 6376208
Drug: Chlorthalidone 50
RxNorm normalized name: chlorthalidone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 50 mg alone
Trial: 31810850
Drug: Vacuum-assisted closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum-assisted closure (VAC) therapy
Trial: 26559710
Drug: Daily changes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily changes in MVPA
Trial: 19884268
Drug: Nonpharmacological treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacological treatments
Trial: 17572579
Drug: Evolence30 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolence30 (30 mg/ml)
Trial: 12137881
Drug: Gonadotropin therapy
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin therapy (three cycles of urinary or recombinant gonadotropins)
Trial: 10981089
Drug: Various classes
RxNorm normalized name: VARIOUS DRUG CLASSES IN ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various classes of blood pressure-lowering agents
Trial: 2206033
Drug: Lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 40 mg once a day with the morning meal (qam)
Trial: 2206033
Drug: Lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 40 mg once a day with the evening meal (qpm)
Trial: 2206033
Drug: Lovastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 80 mg qpm
Trial: 2646895
Drug: Probucol 500
RxNorm normalized name: probucol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 500 mg twice daily
Trial: 388220
Drug: Prednisone (alternate-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (alternate-day treatment for at least eight weeks)
Trial: 29411238
Drug: Home hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home hospital care (nurse and physician home visits, intravenous medications, continuous monitoring, video communication, point‐of‐care testing)
Trial: 27475700
Drug: Topical gel
RxNorm normalized name: Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel containing chitosan, 0.2% chlorhexidine, allantoin and dexpanthenol applied 10 ml three times a day for 10 days
Trial: 24608624
Drug: Oral valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valacyclovir for 1 week
Trial: 18806028
Drug: Closed-loop control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop control system for propofol administration
Trial: 15577823
Drug: Tacrolimus (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (0.1 mg/kg)
Trial: 11379646
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of local anesthetic (Group II)
Trial: 11379646
Drug: Intravenous opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous opioid (Group III)
Trial: 9249783
Drug: Nitrendipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (2 x 5 mg daily for normotensive patients; 2 x 10 mg to 2 x 20 mg daily for hypertensive patients)
Trial: 8491391
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate 480 mg/day plus amoxycillin from days 1 to 7 and tinidazole from days 8 to 14
Trial: 8491391
Drug: Sucralphate 4
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralphate 4 g/day
Trial: 2891631
Drug: Laparoscopic fulguration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic fulguration of endometriotic implants (Group A)
Trial: 2891631
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group B) - implants left intact
Trial: 27677562
Drug: Urate levels
RxNorm normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Urate levels equal to or above the median (5.1 mg/dl)
Trial: 22300367
Drug: Curcumin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (2 g)
Trial: 22300367
Drug: Sulphasalazine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine (100 µg or 2 g) alone
Trial: 19563327
Drug: Branemark implant
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Branemark implant system (two-stage screw type)
Trial: 17993763
Drug: Trandolapril 0.5
RxNorm normalized name: trandolapril 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril 0.5 mg qd
Trial: 11605101
Drug: Alcohol (4.35+/‐0.53
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (4.35+/‐0.53 g/kg per week)
Trial: 9481347
Drug: Whirlpool therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whirlpool therapy
Trial: 8038616
Drug: 5% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% human serum albumin (0.01 ml/kg)
Trial: 20796082
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (LD)
Trial: 20796082
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (HD)
Trial: 19327226
Drug: Educational program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational program intervention (6-week program, weekly sessions lasting 1 hour each)
Trial: 17449497
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin to maintain blood glucose <10 mmol/l
Trial: 17449497
Drug: 200 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g/day of glucose infusion (control group)
Trial: 17449497
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (200 g/day of glucose infusion)
Trial: 11477965
Drug: Vi polysaccharide
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi polysaccharide vaccine (30 micrograms)
Trial: 2483018
Drug: Preoperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative administration of dextran
Trial: 30694077
Drug: Oral oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestradiol (4 mg/d) plus vaginal progesterone (90 mg, 2×1/day)
Trial: 30694077
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (90 mg, 2×1/day) alone
Trial: 25499165
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (maintaining haemoglobin level at 100 g/L or higher)
Trial: 25499165
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (transfusion when haemoglobin level lower than 80 g/L or symptoms of anaemia)
Trial: 19592630
Drug: Metformin, pioglitazone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin, pioglitazone, and glyburide (oral group)
Trial: 17242671
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (platin-based chemotherapy)
Trial: 17242671
Drug: Platin-based chemotherapy
RxNorm normalized name: platinic chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platin-based chemotherapy
Trial: 17242671
Drug: Modified schedules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified schedules or attenuated dose of platin-containing chemotherapy
Trial: 11194113
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (CrS, 20 g x d(‐1) of Cr)
Trial: 27188901
Drug: HMB (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB (3 g · day(‐1))
Trial: 23021204
Drug: Radium-223 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radium-223 (50 kBq/kg, 4 injections every 4 weeks)
Trial: 11434648
Drug: Arginine-enriched formula
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine-enriched formula (6.3 g/L)
Trial: 7851710
Drug: Beta-adrenergic treatment
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenergic treatment
Trial: 2572261
Drug: xamoterol treatment
RxNorm normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xamoterol treatment
Trial: 31961963
Drug: Tadalafil +
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil + Mirabegron (5 mg/50 mg/day)
Trial: 31961963
Drug: Tadalafil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (5 mg/day)
Trial: 20835873
Drug: Transdermal granisetron
RxNorm normalized name: granisetron Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal granisetron (GTDS), one patch for 7 days
Trial: 20835873
Drug: Oral granisetron,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral granisetron, 2 mg/day for 3-5 days
Trial: 12601675
Drug: WS(R) 1340
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WS(R) 1340 (90 mg peppermint oil)
Trial: 12601675
Drug: WS(R) 1520
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WS(R) 1520 (50 mg caraway oil)
Trial: 30762399
Drug: Brief Behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Behavioral Therapy for Cancer‐Related Insomnia (BBT‐CI)
Trial: 30077640
Drug: Pemafibrate (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemafibrate (0.4 mg/d, twice daily for 4 weeks)
Trial: 21264453
Drug: Low-dose cyclosporin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporin A (CsA) 2.5 mg/kg
Trial: 21264453
Drug: Low-dose cyclosporin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporin A (CsA)
Trial: 17199455
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (3-month treatment with a 1-month taper)
Trial: 10868348
Drug: Brief individual
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief individual counseling and weekly newsletters (intervention)
Trial: 3935013
Drug: Education program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education program regarding asthma and asthma medications during four monthly visits
Trial: 22906794
Drug: Experimental arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental arm (n = 18) - shown detailed PSG data, including graphic data from PSG prior to prescription of CPAP
Trial: 20189492
Drug: Investigational hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational hepatitis B vaccine (spHB), 10 microg HBsAg/dose for 10-15 years age group; 20 microg HBsAg/dose for 16-45 years age group, administered in a 0, 1, 6 month schedule.
Trial: 20189492
Drug: Licensed control
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Licensed control vaccine (Engerix B), administered in a 0, 1, 6 month schedule.
Trial: 10372701
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human GH (rhGH) treatment; mean dosage 1.0 U/day for men and 1.9 U/day for women (P < 0.01)
Trial: 10372701
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human GH (rhGH) treatment
Trial: 1941495
Drug: CPC mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPC mouthrinse used as an adjunct to oral hygiene before toothbrushing
Trial: 1941495
Drug: Placebo mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mouthrinse used as an adjunct to oral hygiene before toothbrushing
Trial: 25809373
Drug: Edoxaban (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (60 mg for 3 months or 30 mg with increased exposure factors) + Aspirin (100 mg/d for 6 months)
Trial: 25809373
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg/d for 3 months) + Aspirin (100 mg/d for 6 months)
Trial: 24010849
Drug: Study Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Group (SG) - hemodynamic therapy guided by pulse pressure variation, cardiac index trending, and mean arterial pressure.
Trial: 24010849
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (CG) - hemodynamic therapy at the discretion of the treating anesthesiologist.
Trial: 21504240
Drug: Budesonide/formoterol added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol added to tiotropium (Symbicort® Turbuhaler® 320/9 μg twice daily + tiotropium 18 μg daily)
Trial: 21504240
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to tiotropium (tiotropium 18 μg daily)
Trial: 11544424
Drug: Daclizumab (Zenapax®,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (Zenapax®, Roche Pharmaceuticals)
Trial: 8433235
Drug: Maltodextrin-containing oral
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin-containing oral rehydration solution
Trial: 6115808
Drug: LH-RH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH-RH treatment
Trial: 25335387
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy without magnesium deficiency correction
Trial: 23720246
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (ibuprofen sustained-release)
Trial: 23720246
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (ibuprofen sustained-release)
Trial: 10499756
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (30 microg/kg followed by 3 microg/kg/h for 3 days)
Trial: 10499756
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (0.05-0.1 mg/kg intraoperatively, followed by 0.02 mg/kg doses postoperatively)
Trial: 10499756
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Epidural and Intravenous)
Trial: 8560681
Drug: Bicalutamide 50
RxNorm normalized name: bicalutamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 50 mg monotherapy
Trial: 8560681
Drug: Bicalutamide 50
RxNorm normalized name: bicalutamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 50 mg plus LHRH-A
Trial: 30474791
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV ibuprofen (800 mg)
Trial: 30321520
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV acetaminophen (1000 mg)
Trial: 31012040
Drug: Control (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (100 ml saline solution)
Trial: 31442441
Drug: Lactic-acid-containing diaphragm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactic-acid-containing diaphragm gel (Contragel®)
Trial: 31442441
Drug: Hydroxyethylcellulose (HEC)
DrugBank: Hydroxyethyl cellulose (DB11602)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethylcellulose (HEC) universal placebo gel
Trial: 28363270
Drug: Cortisone Injections
RxNorm normalized name: cortisone Injectable Product
DrugBank: Cortisone (DB14681)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisone Injections
Trial: 31152334
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioral therapy for insomnia (CBT-I)
Trial: 12560782
Drug: Piperacillin/tazobactam 3.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam 3.375 g every 6 hours
Trial: 8807592
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) 5 mg/day s.c during treatment period (Tx) for 7 days
Trial: 8807592
Drug: Post-treatment period
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment period (PostGH) after discontinuation of rhGH
Trial: 6094868
Drug: SBT/CPZ at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBT/CPZ at 20 mg/kg
Trial: 6094868
Drug: SBT/CPZ at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBT/CPZ at 40 mg/kg
Trial: 30325529
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol for four days
Trial: 29924745
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (TEX, 100 mg·wk)
Trial: 29924745
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (PEX)
Trial: 26432791
Drug: Pavlik harness
RxNorm normalized name: HARNESS,PROREN UNDERGARMENT 2XL/3XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pavlik harness treatment (group I: start within 10 days, group II: 11 days to 3 weeks, group III: after 4 weeks)
Trial: 7767393
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of 250iu of anti-D Ig given at 28 and 34 weeks gestation
Trial: 2310093
Drug: Amiloride inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride inhalation (10(‐3) M)
Trial: 2310093
Drug: Amiloride inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride inhalation (2 times a day for 3 weeks)